thalidomide has been researched along with Carcinoma, Squamous Cell of Head and Neck in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, RJ | 1 |
| Saloura, V | 1 |
| Jain, A | 1 |
| Goloubeva, O | 1 |
| Wong, S | 1 |
| Kronsberg, S | 1 |
| Nagilla, M | 1 |
| Silpino, L | 1 |
| de Souza, J | 1 |
| Seiwert, T | 1 |
| Vokes, E | 1 |
| Villaflor, V | 1 |
| Cohen, EE | 1 |
1 trial available for thalidomide and Carcinoma, Squamous Cell of Head and Neck
| Article | Year |
|---|---|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |